Free Trial

Barinthus Biotherapeutics (BRNS) Competitors

Barinthus Biotherapeutics logo
$1.36 +0.05 (+3.82%)
Closing price 03:59 PM Eastern
Extended Trading
$1.38 +0.02 (+1.84%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BRNS vs. KYTX, PBYI, RENB, OGI, PRQR, JMAC, HRTX, VOR, ENTA, and SGMT

Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Kyverna Therapeutics (KYTX), Puma Biotechnology (PBYI), Lunai Bioworks (RENB), Organigram Global (OGI), ProQR Therapeutics (PRQR), Maxpro Capital Acquisition (JMAC), Heron Therapeutics (HRTX), Vor Biopharma (VOR), Enanta Pharmaceuticals (ENTA), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry.

Barinthus Biotherapeutics vs. Its Competitors

Barinthus Biotherapeutics (NASDAQ:BRNS) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Barinthus Biotherapeutics has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Barinthus Biotherapeutics$14.97M3.70-$61.07M-$1.73-0.79
Kyverna Therapeutics$7.03M41.59-$127.48M-$3.68-1.84

In the previous week, Kyverna Therapeutics had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 5 mentions for Kyverna Therapeutics and 3 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.95 beat Kyverna Therapeutics' score of 0.56 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Barinthus Biotherapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kyverna Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Barinthus Biotherapeutics has a beta of -0.71, indicating that its share price is 171% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.72, indicating that its share price is 272% more volatile than the S&P 500.

Barinthus Biotherapeutics currently has a consensus price target of $3.00, indicating a potential upside of 120.59%. Kyverna Therapeutics has a consensus price target of $19.00, indicating a potential upside of 181.07%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Barinthus Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Barinthus Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Barinthus Biotherapeutics' return on equity of -54.70% beat Kyverna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Barinthus BiotherapeuticsN/A -54.70% -44.75%
Kyverna Therapeutics N/A -64.98%-56.17%

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Barinthus Biotherapeutics beats Kyverna Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BRNS vs. The Competition

MetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$55.38M$3.36B$6.02B$10.45B
Dividend YieldN/A2.31%5.73%4.82%
P/E Ratio-0.7922.0385.1227.24
Price / Sales3.70472.74589.92133.47
Price / CashN/A44.9825.7730.18
Price / Book0.4210.4312.676.76
Net Income-$61.07M-$52.58M$3.32B$276.59M
7 Day Performance-14.03%0.98%0.50%0.86%
1 Month Performance23.64%14.76%9.42%8.17%
1 Year Performance16.24%21.29%79.11%43.66%

Barinthus Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BRNS
Barinthus Biotherapeutics
2.459 of 5 stars
$1.36
+3.8%
$3.00
+120.6%
+12.0%$55.38M$14.97M-0.79107Analyst Forecast
KYTX
Kyverna Therapeutics
1.766 of 5 stars
$5.41
-8.1%
$16.60
+206.8%
+32.0%$254.72M$7.03M-1.4796Analyst Forecast
Gap Down
PBYI
Puma Biotechnology
4.1268 of 5 stars
$5.18
+3.0%
$7.00
+35.1%
+85.6%$253.37M$230.50M5.29200Positive News
RENB
Lunai Bioworks
0.7166 of 5 stars
$1.54
+21.7%
N/A-69.8%$250.24MN/A-2.0020Positive News
Gap Down
OGI
Organigram Global
1.1707 of 5 stars
$1.96
+5.9%
N/A+11.6%$248.53M$117.47M39.21860
PRQR
ProQR Therapeutics
2.0094 of 5 stars
$2.27
-3.8%
$8.00
+252.4%
+23.8%$248.30M$20.46M-4.93180News Coverage
Positive News
JMAC
Maxpro Capital Acquisition
N/A$18.43
flat
N/AN/A$247.52MN/A0.002,021
HRTX
Heron Therapeutics
4.1034 of 5 stars
$1.32
-1.5%
$4.50
+240.9%
-29.3%$245.64M$144.29M-66.00300
VOR
Vor Biopharma
3.1868 of 5 stars
$33.80
-5.3%
$113.83
+236.8%
N/A$244.58MN/A-0.12140Gap Up
ENTA
Enanta Pharmaceuticals
4.0187 of 5 stars
$11.08
-2.4%
$20.83
+88.0%
+4.1%$242.64M$67.64M-2.56160
SGMT
Sagimet Biosciences
2.7887 of 5 stars
$7.34
+0.4%
$25.67
+249.7%
+76.3%$237.73M$2M-4.018News Coverage
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:BRNS) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners